Actively Recruiting
The Effect of the Nutraceutical (-)- Epicatechin on Myosteatosis in Patients With Advanced CKD
Led by Karolinska Institutet · Updated on 2025-07-10
10
Participants Needed
1
Research Sites
88 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Some foods have components that can prevent and treat some diseases and provide beneficial effects for health. These components naturally occurring in foods are called nutraceuticals. Recently, it was found that Epicatechin, which is a kind of nutraceutical from the Catechin's family naturally occurring in green tea and cocoa, has positive effects on muscle mass and strength of people with chronic diseases. People with chronic kidney disease often present muscle loss and lack of strength that are not easily treated with regular diet and physical activity. We here propose a study where 10 individuals with chronic kidney disease will receive a dose of Epicatechin for 8 weeks and we aim to test if Epicatechin improves general muscle health. Based on what is known, we expect to see an increase in muscle mass and strength. The dose of Epicatechin provided (100 mg/day) is safe, since it is much lower than the dose usually available in supplements. In addition, this is the form naturally present in green tea and cocoa and in similar amounts. Subjects participating in the study will be evaluated for muscle mass and strength three times during the study. Muscle mass and muscle quality will be evaluated by ultrasound and magnetic resonance imaging. The participants will also perform some tests like walking in a corridor and seating and standing from a chair to measure their strength and performance. Adverse side effects will be monitored via telephone, and safety will be assessed by monthly blood tests that will evaluate liver and kidney function. If this study shows that Epicatechin can promote muscle growth and strength, it will positively affect patients with chronic kidney disease that might benefit of a natural substance from food to improve muscle health.
CONDITIONS
Official Title
The Effect of the Nutraceutical (-)- Epicatechin on Myosteatosis in Patients With Advanced CKD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Estimated glomerular filtration rate (eGFR) less than 29 ml/min/1.75m2
- No known chronic or acute liver disease
- Not expected to start renal replacement therapy in the next 4 months according to nephrologist judgment
You will not qualify if you...
- Signs of active infection
- Acute vasculitis
- Type 1 diabetes
- Use of steroid medications
- Transplanted patients
- Patients with walking impairment (wheelchair users, bed rest)
- Patients receiving compassionate care for end of life
- Advanced neurological disorders
- Cognitive impairments
- Active cancer diagnosis
- Participation in another interventional trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Karolinska University Hospital
Huddinge, Stockholm County, Sweden, 14152
Actively Recruiting
Research Team
A
Alice Sabatino, PhD
CONTACT
P
Peter Stenvinkel, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
CROSSOVER
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here